According to a recent report in Cancer Network, the results from CARTITUDE-1 were well received. CARTITUDE-1 is a phase 1b/2 clinical trial of the CAR T-cell treatment, Cilta-Cel, for the…
According to a story from Cancer Therapy Advisor, a recent phase 1 clinical trial investigated an experimental CAR T-cell therapy in heavily pretreated patients living with multiple myeloma, a rare…
According to Biospace, Allogene's trial of ALLO-715 for relapsed/refractory multiple myeloma was marred by a patient death. Data from this trial is slated to be presented in December at the…
Damian Green from the University of Washington is the Principal Investigator for a new research project in multiple myeloma. This project is thanks to a research agreement between the Fred…
According to a story from BioSpace, Takeda Pharmaceutical Company Ltd. recently announced the release of results from a phase 3 clinical trial. This trial was testing the company's drug ixazomib…
In a recent press release, Swedish biotechnology company Active Biotech announced that the first patient in their Phase 1b/2a clinical trial received a dose of tasquinimod. The trial will…
According to a story from GlobeNewswire, the first patient has been dosed in a recent clinical trial testing the experimental therapy tasquinimod as a treatment for multiple myeloma, a rare…
According to data from the STOMP trial involving thirty-four patients, a triple regimen has been proven to induce durable responses in pretreated patients with relapsed/refractory multiple myeloma. A recent…
According to a recent article in the Myasthenia Gravis News, a team of doctors in Japan had been treating a man now aged sixty for multiple myeloma (MM). The…
According to a story from Myasthenia Gravis News, a recent case report describes a unique case of a 60 year old male multiple myeloma patient. After receiving treatment for the…
Although we may feel like the world is stopped, thanks to COVID-19, many companies consistently push for technological advances. According to Myeloma Research News, GNS Healthcare is one of those…
According to the ASCO Post, researchers have discovered genomic characteristics of smoldering multiple myeloma that can tell one's risk of progression to multiple myeloma. Dr. Mark Bustoros and his team…
According to a recent press release, biopharmaceutical company CASI Pharmaceuticals filed a Clinical Trial Application (CTA) (IND) in the United Kingdom. CASI Pharmaceuticals is hoping to test the safety…
According to the American Journal of Managed Care, a case study in China has shown that tocilizumab was effective in treating a patient with both COVID-19 and multiple myeloma. When…
According to a story from LocalHealthGuide, COVID-19 has continued to spread through the US and the lackluster government response suggests that it isn't going to be contained any time soon.…
According to a story from businesswire.com, the Bristol Myers Squibb Company recently released the topline results from its phase 3 clinical trial. This study was testing a combination treatment consisting…
Sarclisa was recently approved for the treatment of multiple myeloma when taken with pomalidomide and dexamethasone. The FDA indicated that this treatment is for those who have been treated with…
A study published on February 3rd, 2020 in the scientific journal Nature Research is highlighting the capability of a three part combination treatment for use in multiple myeloma, a rare and…
.jpg)
According to a report in Myeloma Research News, the European Commission has recently granted authorization to market bortezomib, dexamethasone and thalidomide (collectively known as VTd) plus daratumumab to treat…
According to a story from Financial Buzz, the precision oncology company Notable has recently announced that it has opened enrollment for a new observational clinical trial that will focus on…
.jpg)
The biopharmaceutical company Cellectar Biosciences recently announced that the FDA granted its lead phospholipid drug conjugate, CLR 131, Orphan Drug Designation(ODD) for treatment of lymphoplasmacytic lymphoma. ODD is granted by…
Copyscape score: 4% Cancer is a disease that affects different people in different ways, and for some people, no existing treatments can effectively treat their cancer. GlaxoSmithKline has recently released…
According to a story from BioPortfolio, the drug companies bluebird bio, Inc. and the Bristol-Myers Squibb Company have recently announced positive final results for their phase 2 clinical trial. This…
.jpg)
According to a recently published article in Targeted Oncology, the results of the Phase III CANDOR trial were presented at the 61st ASH annual conference in Orlando, Florida. The…
.jpg)
According to a recent article in the ASH Clinical News patients are being encouraged to participate in shared decision-making (SDM) with their doctors, nurses and other medical personnel. The…
© Copyright Patient Worthy
